Skip to main content

Table 2 Per-patient sensitivity, specificity and diagnostic odds ratio (DOR), with 95% confidence intervals of mannan antigen (Mn), anti-mannan antibodies (A-Mn) and combined Mn/A-Mn testing for separate studies, median of the studies and totala

From: The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia

Study

Sensitivity (95% CI), absolute numbers:

true positives/total

Specificity (95% CI), absolute numbers:

true negatives/total

DOR (95% CI)

 

Mn

A-Mn

Mn/A-Mn

Mn

A-Mn

Mn/A-Mn

Mn

A-Mn

Mn/A-Mn

1. Verduyn Lunel et al., 2009 [31]

0.38 (0.18-0.62), 8/21

0.52 (0.30-0.74), 11/21

0.71 (0.48-0.89), 15/21

0.83 (0.65-0.94), 25/30

0.90 (0.73-0.98), 27/30

-

3.1 (0.8-11.3)

9.9 (2.3-43)

-

2. Ellis et al., 2009 [26]b

0.75 (0.43-0.95), 9/12

1.00 (0.74-1.00), 12/12

1.00 (0.74-100), 12/12

0.65 (0.53-0.76), 48/74

0.38 (0.27-0.50), 28/74

0.80 (0.69-0.88), 59/74

5.5 (1.4-22.3)

15.3 (0.9-268.9)

96 (5.4-1712)

3. Sendid et al., 2008 [37]

0.67 (0.41-0.87), 12/18

0.78 (0.52-0.94), 14/18

0.94 (0.73-0.99), 17/18

-

-

-

-

-

-

4. Oliveri et al., 2008 [24]

0.94 (0.73-0.99), 17/18

-

-

0.94 (0.84-0.99), 49/52

-

-

277.7 (27-2852.3)

-

-

5. Alam et al., 2007 [28]

0.48 (0.29-0.68), 13/27

0.52 (0.32-0.71), 14/27

0.81 (0.62-0.94), 22/27

1.00 (0.87-1.00), 26/26

0.92 (0.75-0.99), 24/26

0. 92 (0.75-0.99), 24/26

49.3 (2.7-891.8)

12.9 (2.5-65.8)

52.8 (9.3-300.5)

6. Fujita et al., 2006 [29]

0.53 (0.43-0.63), 56/105

-

-

0.92 (0.87-0.96), 161/175

  

13.1 (6.7-25.6)

-

-

7. Prella et al., 2005 [25]

0.31 (0.14-0.52), 8/26

0.81 (0.61-0.93), 21/26

0.88 (0.70-0.98), 23/26

0.96 (0.80-0.99), 24/25

0.88 (0.69-0.97), 22/25

0.84 (0.64-0.95), 21/25

(all 4 colonised)

10.7 (1.2-93.1)

30.8 (6.5-145.3)

40.3 (8.1-201.3)

8. White et al., 2005 [32]

0.75 (0.51-0.91), 15/20

-

-

0.97 (0.90-0.99), 65/67

-

-

97.5 (17.2-551.8)

-

-

9. Sendid et al., 2004 [33]

0.69 (0.48-0.86), 18/26

-

-

0.97 (0.93-0.99), 115/118

-

-

86.3 (20.9-355.7)

-

-

10. Sendid et al., 2003 [27]

1.00 (0.59-1.00), 7/7

0.71 (0.29-0.96), 5/7

1.00 (0.59-1.00), 7/7

0.92 (0.62-0.99), 11/12

1.00 (0.74-1.00), 12/12

0.92 (0.62-0.99), 11/12

115 (4.1-3213.5)

55 (2.2-1346,2)

115 (4.1-3213.5)

11. Sendid et al., 2002 [17]

0.52 (0.39-0.65), 33/63

0.44 (0.32-0.58), 28/63

0.76 (0.64-0.86), 48/63

-

-

-

-

-

-

12. Persat et al., 2002 [34]

0.86 (0.65-0.97), 19/22

0.59 (0.36-0.79), 13/22

0.95 (0.77-0.99), 21/22

0.79 (0.63-0.90), 30/38

0.63 (0.46-0.78), 24/38

0.53 (0.36-0.69), 20/38

23.8 (5.6-100.8)

2.48 (0.9-7.3)

23.3 (2.8-191.5)

13. Yera et al., 2001 [18]

0.58 (0.42-0.72), 26/45

0.53 (0.38-0.68), 24/45

0.78 (0.63-0.89), 35/45

-

-

-

-

-

-

14. Sendid et al., 1999 [16]

0.42 (0.27-0.58), 18/43

0.56 (0.40-0.71), 24/43

0.84 (0.69-0.93), 36/43

0.98 (0.94-0.99), 147/150

0.97 (0.92-0.99), 145/150

0.95 (0.90-0.98), 142/150

35.3 (9.7-128.6)

36.6 (12.5-107.4)

91.3 (31.1-268.4)

Median of all the studies (range)

0.62 (0.31-1.0)

0.57 (0.44-1.0)

0.86 (0.71-1.0)

0.94 (0.65-1.0)

0.9 (0.38-1.0)

0. 88 (0.53-0.92)

   

Pooled overall

0.58 (0.53-0.62), 259/453

0.59 (0.54-0.65), 166/284 2

0.83 (0.79-0.87), 236/284c

0.93 (0.91-0.94), 701/767d

0.83 (0.79-0.87), 282/355e

0.86 (0.82-0.90), 277/325f

18.6 (12.5-27.7)d

12.1 (7-20.8)e

57.5 (27.1-122)f

  1. aNR, not reported; -, no data. bAbsolute numbers calculated on basis of reported percentage sensitivity and specificity values. cAvailable for 10 studies. dData from 11 studies. eData from 7 studies. fData from 6 studies.